Allergan Sues Hi-Tech To Block Generic Lash Drug Latisse

Law360, New York (May 16, 2012, 7:17 PM EDT) -- Allergan Inc. filed its third patent infringement suit against Hi-Tech Pharmacal Co. Inc. in North Carolina federal court on Wednesday, its latest effort to block a generic version of the eyelash growth treatment Latisse.

Allergan claims Hi-Tech's abbreviated new drug application seeking permission to manufacture bimatoprost ophthalmic solution infringes its patent for the drug. The treatment is marketed as Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers who want longer or thicker lashes....
To view the full article, register now.